TCGA-FD-A5BZ-01A-11R-A28M-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 27.43101183
- os_event
- true
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.630
- ANGIOGENESIS+0.460
- UV_RESPONSE_DN+0.420
- TGF_BETA_SIGNALING+0.380
- APICAL_JUNCTION+0.370
- HEDGEHOG_SIGNALING+0.340
- COAGULATION+0.300
- MYOGENESIS+0.300
- KRAS_SIGNALING_UP+0.260
- ESTROGEN_RESPONSE_EARLY+0.240
Top 10 suppressed
- MYC_TARGETS_V1-0.460
- E2F_TARGETS-0.440
- ALLOGRAFT_REJECTION-0.400
- G2M_CHECKPOINT-0.400
- MYC_TARGETS_V2-0.400
- OXIDATIVE_PHOSPHORYLATION-0.330
- MTORC1_SIGNALING-0.200
- PANCREAS_BETA_CELLS-0.200
- SPERMATOGENESIS-0.200
- IL6_JAK_STAT3_SIGNALING-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-86-6562-01A-11R-1755-07 | — | cohortA1 | 0.864 |
| 2 | TCGA-EW-A1PF-01A-11R-A144-07 | — | A | 0.858 |
| 3 | TCGA-D8-A146-01A-31R-A115-07 | — | A | 0.858 |
| 4 | TCGA-A1-A0SH-01A-11R-A084-07 | — | A | 0.849 |
| 5 | 20020009.LumA | — | A | 0.845 |
| 6 | SRR2932823 | — | — | 0.842 |
| 7 | TCGA-DK-A2HX-01A-12R-A18C-07 | — | — | 0.841 |
| 8 | 22620634-aa34-4cb5-a37f-5a7b0c47cd0e | — | — | 0.838 |
| 9 | 6b548699-9440-4acc-86b6-faeb367454a2 | — | — | 0.833 |
| 10 | TCGA-AN-A0XL-01A-11R-A10J-07 | — | A | 0.824 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.630 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.460 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.420 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.380 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.370 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.340 | Inavolisib | — uncovered |
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| MYOGENESIS | 0.300 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.260 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.240 | Inavolisib | — uncovered |
| HYPOXIA | 0.230 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.230 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.230 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.220 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.210 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.190 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.150 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.140 | Inavolisib | — uncovered |
| APOPTOSIS | 0.140 | Idelalisib | — uncovered |
| PEROXISOME | 0.140 | Idelalisib | — uncovered |